Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation

被引:37
|
作者
Skidmore, F. M. [1 ]
Drago, V. [2 ]
Foster, P. [2 ]
Schmalfuss, I. M. [3 ]
Heilman, K. M. [2 ]
Streiff, R. R. [1 ]
机构
[1] Univ Florida, Sch Med, N Florida S Georgia VA Med Ctr, McKnight Brain Inst,Dept Med,Div Hematol, Gainesville, FL 32610 USA
[2] Univ Florida, Sch Med, Dept Neurol, Gainesville, FL USA
[3] N Florida S Georgia VA Med Ctr, Serv Radiol, Gainesville, FL USA
来源
关键词
D O I
10.1136/jnnp.2007.120568
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Hereditary aceruloplasminaemia is a disorder of iron metabolism that is characterised by iron accumulation in the brain and other visceral organs. In previously reported cases, individuals with the disorder were noted to have evidence of iron accumulation in the brain. Oral chelating agents have not been used in neurological diseases of iron metabolism. Methods: A 54-year-old woman who presented with ataxia, lower extremity spasticity and chorea was evaluated for evidence of the source of neurological dysfunction. Results: Blood studies revealed no detectable ceruloplasmin. Marked iron overload was defined by a liver biopsy, which showed a variegated pattern consistent with a primary cause of iron overload. Review of MRI scans showed progressive brain atrophy without visible iron accumulation occurring over a 5-year period. The history suggested that neurodegeneration was coincident with aggressive oral iron replacement. Oral chelation improved many symptoms. Conclusions: Our findings in this patient suggest that disorders of iron transport such as aceruloplasminaemia can be a cause of neurological symptoms such as chorea and cognitive decline, as well as progressive neurodegeneration in the absence of visible iron on MRI scans. We found that oral iron chelation was effective at improving symptoms.
引用
收藏
页码:467 / 470
页数:4
相关论文
共 50 条
  • [31] Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia - A Prospective Observational Study
    DivakarJose, Rajeswari Rethinaswamy
    Delhikumar, C. G.
    Kumar, G. Ram
    INDIAN JOURNAL OF PEDIATRICS, 2021, 88 (04): : 330 - 335
  • [32] Efficacy and Safety of Combined Oral Chelation with Deferiprone and Deferasirox on Iron Overload in Transfusion Dependent Children with Thalassemia – A Prospective Observational Study
    Rajeswari Rethinaswamy DivakarJose
    C. G. Delhikumar
    G. Ram Kumar
    Indian Journal of Pediatrics, 2021, 88 : 330 - 335
  • [33] A novel approach to iron chelation therapy: Twice-daily subcutaneous injections of deferoxamine in the treatment of transfusional iron overload in pediatric patients.
    Medini, I
    McDonough, EA
    Nelson, SC
    BLOOD, 1998, 92 (10) : 31B - 31B
  • [34] Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease
    Chan, JCW
    Chim, CS
    Ooi, CGC
    Cheung, B
    Liang, R
    Chan, TK
    Chan, V
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 (02) : 198 - 205
  • [35] EVALUATION INVIVO OF HYDROXYPYRID-4-ONE IRON CHELATORS INTENDED FOR THE TREATMENT OF IRON OVERLOAD BY THE ORAL ROUTE
    GYPARAKI, M
    PORTER, JB
    HUEHNS, ER
    HIDER, RC
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1986, 14 (06) : 1181 - 1181
  • [36] Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy
    Han, Yong-Hee
    Lee, Jae-Hyeok
    Kang, Bok-Man
    Mun, Chi-Woong
    Baik, Seung-Kug
    Shin, Yong-il
    Park, Kyu-Hyun
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2013, 325 (1-2) : 29 - 35
  • [37] COST-EFFECTIVENESS OF IRON CHELATION THERAPIES FOR THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN B-THALASSAEMIA, SICKLE CELL DISEASE, AND MYELODYSPLASTIC SYNDROME: A LITERATURE REVIEW
    Ahmed, W.
    Rethmeier, L.
    Nottmeier, M.
    Pollock, R. F.
    VALUE IN HEALTH, 2022, 25 (12) : S187 - S187
  • [38] Non-transferrin-bound iron (NTBI) in sera of thalassemic patients during oral chelation treatment.
    Breuer, W
    Ronson, A
    Abramov, A
    Pootrakul, P
    Hershko, C
    Cabantchik, IZ
    BLOOD, 1999, 94 (10) : 422A - 422A
  • [39] The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia
    Nyffenegger, Naja
    Flace, Anna
    Doucerain, Cedric
    Duerrenberger, Franz
    Manolova, Vania
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (02) : 1 - 11
  • [40] ORAL 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE FOR THE TREATMENT OF TRANSFUSIONAL IRON OVERLOAD
    KONTOGHIORGHES, GJ
    SHEPPARD, L
    ALDOURI, MA
    WONKE, B
    BARR, J
    HOFFBRAND, AV
    BRITISH JOURNAL OF HAEMATOLOGY, 1988, 68 (04) : 508 - 508